FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2318470140> ?p ?o ?g. }

• W2318470140 endingPage "A394" @default.
• W2318470140 startingPage "A394.2" @default.
• W2318470140 abstract "<h3>Background</h3> Therapeutic advances have made low disease-activity states (LDAS) and remission increasingly common for patients with rheumatoid arthritis (RA) [1]. In order to achieve and maintain tight-control of disease activity, it is essential to identify predictors of sustained remission A multi-biomarker disease activity (MBDA) score has been validated to assess disease activity in patients with RA. We examined these serum biomarkers as predictors of sustained remission. <h3>Objectives</h3> To explore the use of the MBDA score and its components to predict sustained remission in patients from the REMIRA cohort. <h3>Methods</h3> The study was conducted on 95 patients from the Remission in RA (REMIRA) cohort (disease duration <10 years, stable therapy > 6 months and DAS28-ESR<3.2) [1]. Patients were assessed every 3 months for 1 year. Serum concentrations of VCAM-1, EGF, VEGF-A, IL-6, TNF-RI, YKL-40, MMP-1, MMP-3, leptin, resistin, SAA, and CRP were measured at baseline by multiplex immunoassay and combined using the validated Vectra DA algorithm to generate a MBDA score (range 1-100) [2]. Clinical remission was defined by EULAR 2011 Boolean criteria and SDAI, CDAI, and DAS28-ESR scores. ‘Sustained remission’ was defined as achieving remission at all time points. ‘Intermittent remission’ was defined as remission at ≥1 time point but not all. <h3>Results</h3> The mean (±SD) baseline (BL) characteristics were: age 56 (±17), disease duration 50 months (±31), 61% female and 88% were RF positive, DAS28-ESR 2.10 (±0.96) and MBDA score 31.4 (±12.66). At BL, 31%, 49%, 49% and 67% of these patients were in remission according to Boolean, SDAI, CDAI and DAS28-ESR criteria respectively. Of those in remission, 28%, 48%, 50% and 69% achieved sustained remission using the same criteria over 1 year. Lower BL MBDA score, CRP, SAA, and IL-6 were associated with sustained remission defined by DAS28-ESR, SDAI, CDAI and Boolean criteria. The median BL MBDA score was <25 in all sustained remission groups. Baseline MBDA score inversely correlated with the proportion of visits in remission for all remission criteria. In patients with ≤1 missing data point for each clinical measurement (n=68), BL MBDA score, CRP, SAA and IL-6 could stratify between no, intermittent and sustained remission for at least one of the remission criteria. Only MBDA score was able to stratify across all 4 criteria. By using logistic regression, BL MBDA was not found to be an independent predictor of sustained DAS28-ESR remission if given BL DAS28-ESR. <h3>Conclusions</h3> This study showed that only a subset of patients in LDAS at BL achieved sustained clinical remission over a 1 year period. The rates of sustained remission differed across the 4 remission criteria analyzed. Baseline MBDA score, IL6, SAA, CRP and leptin were associated with sustained remission. Acute phase response markers IL6, SAA and CRP were able to stratify between no, intermittent and sustained remission groups suggesting that persistent inflammation is significant even at low levels of disease activity. <h3>References</h3> Ma MHY et al., Remission in early RA. J Rheumatol.2010; 37(7):1444 Curtis JR, et al., Validation of a novel multi-biomarker test to assess rheumatoid arthritis disease activity. Arthritis Care & Research 2012; 64(12):1794 <h3>Disclosure of Interest</h3> M. Ma Grant/research support from: NIHR, W. Li Shareholder of: Crescendo Bioscience, Employee of: Crescendo Bioscience, N. Defranoux Shareholder of: Crescendo Bioscience, Employee of: Crescendo Bioscience, G. Kingsley: None Declared, D. Scott Grant/research support from: NIHR, A. Cope Grant/research support from: Arthritis Research UK" @default.
• W2318470140 created "2016-06-24" @default.
• W2318470140 creator A5002092452 @default.
• W2318470140 creator A5012639509 @default.
• W2318470140 creator A5018175445 @default.
• W2318470140 creator A5020229499 @default.
• W2318470140 creator A5050928134 @default.
• W2318470140 creator A5074711841 @default.
• W2318470140 date "2013-06-01" @default.
• W2318470140 modified "2023-10-16" @default.
• W2318470140 title "FRI0075 A multi-biomarker disease activity (vectra™ da algorithm) score and components are associated with sustained clinical remission in rheumatoid arthrits: the remira study." @default.
• W2318470140 doi "https://doi.org/10.1136/annrheumdis-2013-eular.1202" @default.
• W2318470140 hasPublicationYear "2013" @default.
• W2318470140 type Work @default.
• W2318470140 sameAs 2318470140 @default.
• W2318470140 citedByCount "1" @default.
• W2318470140 countsByYear W23184701402018 @default.
• W2318470140 crossrefType "journal-article" @default.
• W2318470140 hasAuthorship W2318470140A5002092452 @default.
• W2318470140 hasAuthorship W2318470140A5012639509 @default.
• W2318470140 hasAuthorship W2318470140A5018175445 @default.
• W2318470140 hasAuthorship W2318470140A5020229499 @default.
• W2318470140 hasAuthorship W2318470140A5050928134 @default.
• W2318470140 hasAuthorship W2318470140A5074711841 @default.
• W2318470140 hasConcept C126322002 @default.
• W2318470140 hasConcept C185592680 @default.
• W2318470140 hasConcept C198451711 @default.
• W2318470140 hasConcept C2777178219 @default.
• W2318470140 hasConcept C2777575956 @default.
• W2318470140 hasConcept C2781197716 @default.
• W2318470140 hasConcept C55493867 @default.
• W2318470140 hasConcept C71924100 @default.
• W2318470140 hasConcept C72563966 @default.
• W2318470140 hasConcept C90924648 @default.
• W2318470140 hasConceptScore W2318470140C126322002 @default.
• W2318470140 hasConceptScore W2318470140C185592680 @default.
• W2318470140 hasConceptScore W2318470140C198451711 @default.
• W2318470140 hasConceptScore W2318470140C2777178219 @default.
• W2318470140 hasConceptScore W2318470140C2777575956 @default.
• W2318470140 hasConceptScore W2318470140C2781197716 @default.
• W2318470140 hasConceptScore W2318470140C55493867 @default.
• W2318470140 hasConceptScore W2318470140C71924100 @default.
• W2318470140 hasConceptScore W2318470140C72563966 @default.
• W2318470140 hasConceptScore W2318470140C90924648 @default.
• W2318470140 hasIssue "Suppl 3" @default.
• W2318470140 hasLocation W23184701401 @default.
• W2318470140 hasOpenAccess W2318470140 @default.
• W2318470140 hasPrimaryLocation W23184701401 @default.
• W2318470140 hasRelatedWork W1984273828 @default.
• W2318470140 hasRelatedWork W1987294331 @default.
• W2318470140 hasRelatedWork W2035343580 @default.
• W2318470140 hasRelatedWork W2046399730 @default.
• W2318470140 hasRelatedWork W2094304284 @default.
• W2318470140 hasRelatedWork W2123582592 @default.
• W2318470140 hasRelatedWork W2558297493 @default.
• W2318470140 hasRelatedWork W2736593664 @default.
• W2318470140 hasRelatedWork W2996380604 @default.
• W2318470140 hasRelatedWork W4239841759 @default.
• W2318470140 hasVolume "72" @default.
• W2318470140 isParatext "false" @default.
• W2318470140 isRetracted "false" @default.
• W2318470140 magId "2318470140" @default.
• W2318470140 workType "article" @default.